絞り込み

17875

広告

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.

著者 Casali PG , Le Cesne A , Poveda Velasco A , Kotasek D , Rutkowski P , Hohenberger P , Fumagalli E , Judson IR , Italiano A , Gelderblom H , Adenis A , Hartmann JT , Duffaud F , Goldstein D , Broto JM , Gronchi A , Dei Tos AP , Marréaud S , van der Graaf W
J Clin Oncol.2015 Nov 16 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (3view , 0users)

Full Text Sources

Medical

In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery patients with localized, high- or intermediate-risk GI stromal tumor (GIST).
PMID: 26573069 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード